Parand Darou Pharmaceutical Company, as a knowledge-based company, started its activity with the production of pharmaceutical drugs in 2005 and is the second company in the private sector that received a license to produce drug products from the Food and Drug Organization of Iran. And by extracting opioid raw materials, it has been able to produce effective pharmaceuticals such as codeine phosphate, noscapine, thebaine, papaverine, and oxycodone, and in addition to meeting the needs of domestic customers, it has exported its products to global markets. In 2018, this company was able to enter the production cycle of finished drug products in addition to the production of effective medicinal substances by creating a syrup line and receiving a GMP certificate and a license from the competent authority. Owners of the country's pharmaceutical industry, Kimiagaran Maroz Chemical Industries Company (Public Stock) purchased the management shares of Parand Daro Pharmaceutical Company in July 1401, and by establishing an expert and experienced management team, it intends to create a turning point in the growth, development and excellence of the company.